Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1984 5
1985 5
1986 6
1987 5
1988 13
1989 5
1990 8
1991 3
1992 6
1993 5
1994 13
1995 9
1996 15
1997 10
1998 7
1999 7
2000 8
2001 11
2002 5
2003 13
2004 8
2005 7
2006 7
2007 12
2008 9
2009 15
2010 12
2011 9
2012 13
2013 14
2014 14
2015 9
2016 15
2017 15
2018 12
2019 14
2020 18
2021 19
2022 10
2023 9

Text availability

Article attribute

Article type

Publication date

Search Results

370 results

Results by year

Filters applied: . Clear all
Page 1
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
Colombo N, Gadducci A, Landoni F, Lorusso D, Sabbatini R, Artioli G, Berardi R, Ceccherini R, Cecere SC, Cormio G, De Angelis C, Legge F, Lissoni A, Mammoliti S, Mangili G, Naglieri E, Petrella MC, Ricciardi GRR, Ronzino G, Salutari V, Sambataro D, Savarese A, Scandurra G, Tasca G, Tomao F, Valabrega G, Zavallone L, Pignata S. Colombo N, et al. Among authors: gadducci a. Gynecol Oncol. 2023 Aug;175:182-189. doi: 10.1016/j.ygyno.2023.05.065. Epub 2023 Jun 22. Gynecol Oncol. 2023. PMID: 37355448
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Salutari V, Selle F, Frezzini S, De Giorgi U, Pautier P, Bologna A, Orditura M, Dubot C, Gadducci A, Mammoliti S, Ray-Coquard I, Zafarana E, Breda E, Favier L, Ardizzoia A, Cinieri S, Largillier R, Sambataro D, Guardiola E, Lauria R, Pisano C, Raspagliesi F, Scambia G, Daniele G, Perrone F; MITO16b/MANGO–OV2/ENGOT–ov17 Investigators. Pignata S, et al. Among authors: gadducci a. Lancet Oncol. 2021 Feb;22(2):267-276. doi: 10.1016/S1470-2045(20)30637-9. Lancet Oncol. 2021. PMID: 33539744 Clinical Trial.
Pharmacological treatment for uterine leiomyosarcomas.
Gadducci A, Guerrieri ME. Gadducci A, et al. Expert Opin Pharmacother. 2015 Feb;16(3):335-46. doi: 10.1517/14656566.2015.985205. Epub 2014 Nov 22. Expert Opin Pharmacother. 2015. PMID: 25418060 Review.
The role of HE4 in ovarian cancer follow-up: a review.
Piovano E, Attamante L, Macchi C, Cavallero C, Romagnolo C, Maggino T, Landoni F, Gadducci A, Sartori E, Gion M, Zola P. Piovano E, et al. Among authors: gadducci a. Int J Gynecol Cancer. 2014 Oct;24(8):1359-65. doi: 10.1097/IGC.0000000000000218. Int J Gynecol Cancer. 2014. PMID: 25054447 Free article. Review.
370 results